Checking Vital Signs on Medical-Services Stocks

 | May 04, 2012 | 4:30 PM EDT  | Comments
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

anik

,

knsy

,

elgx

One of the top-performing stocks I have been tracking in model portfolios this year is Anika Therapeutics (ANIK). Before Friday's first-quarter report, the stock had advanced nearly 70% year to date.

However, the maker of treatments for bone and cartilage and ailments gapped down Friday, as the company missed top- and bottom-line views.

Nonetheless, the stock was getting support at its 10-week average, a sign that some of the institutional owners were doing some dip-buying to add to existing positions at a lower price. Even with the sharp decline, the stock is still up about 47% year to date.

Even with the misses, Friday's results represented a whopping 600% year-over-year gain in earnings and a 22% gain on the top-line number. The 10-week support is encouraging, suggesting that after that strong run-up and a much-needed pullback, the stock could set up for further gains.

Yesterday, I wrote about medical-services companies whose stocks are showing leadership above key moving averages. But other sub-industries within the medical sector are also outperforming the majority of stocks in the market.

In Thursday's trade, small-cap Kensey Nash (KNSY) bolted 32% on news that the firm would be acquired by Dutch-based DSM. Kensey Nash makes regenerative products for orthopedic, sports medicine and other surgical applications. While that stock is no longer a viable trade candidate, merger-and-acquisition activity often brings positive attention to other companies in related lines of business.

Several other medical-products makers have shown good chart action in recent weeks, continuing to receive good moving-average support even as the market has trended lower.

Endologix (ELGX), which makes vein treatments, has been getting solid support along its 10-week moving average. Despite the solid chart action, I regard this as a speculative company, because of the lack of earnings thus far.

Of course, this is common in many medical and biotech companies, which are often research-and-development-intensive. These companies frequently put their revenue back into research, meaning that a fundamental analysis that you might do on, say, a retail or info tech company doesn't apply here.

Endologix has reported revenue growth between 22% and 41% in every quarter over the past two years. That indicates strong demand for its products.

The stock cleared a buy point of $14.87 on April 27, shortly after the major indices confirmed a new uptrend with heavy-volume price gains. However, new uptrends are always fragile, and with Friday's market action, it appears to have failed.

As of now, Endologix has fallen from its prior high of $15.29. It is getting support above its 50-day line, but it's in "falling knife" territory at the moment. In other words, until the stock begins to rebound above key moving averages, it is not in a proper buy range. In addition, general market weakness would preclude me from taking a position at this juncture.

This is a small company, with a market cap of just $824 million. It trades around 447,000 shares per day, on average. That's on the thin side, when put in context of the broader market. But for a small-cap name, that's decent liquidity.

As always, these smaller stocks can be more volatile than others, and that means extra caution is required when opening a position. The stock has a beta of 1.16, an indication of its volatility.

Columnist Conversations

The Swiss National Bank feels that too much capital is flowing into the country from places like Russia, where...
Today will be my last webinar of 2014. I will talk about some recent trading activity and give you a peek int...
There was a string of good news out of Germany recently. The latest is that the business confidence indicator,...
AAPL needs to clear this hurdle IF this last low is any good!! View Chart » ...

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.